These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37169499)

  • 1. Patient-reported impact of myasthenia gravis in the real world: findings from a digital observational survey-based study (MyRealWorld MG).
    Berrih-Aknin S; Palace J; Meisel A; Claeys KG; Muppidi S; Saccà F; Amini F; Larkin M; Quinn C; Beauchamp J; Philips G; De Ruyck F; Ramirez J; Paci S
    BMJ Open; 2023 May; 13(5):e068104. PubMed ID: 37169499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-reportedimpact of myasthenia gravis in the real world: protocol for a digital observational study (MyRealWorld MG).
    Berrih-Aknin S; Claeys KG; Law N; Mantegazza R; Murai H; Saccà F; Dewilde S; Janssen MF; Bagshaw E; Kousoulakou H; Larkin M; Beauchamp J; Leighton T; Paci S
    BMJ Open; 2021 Jul; 11(7):e048198. PubMed ID: 34285010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG.
    Dewilde S; Philips G; Paci S; Beauchamp J; Chiroli S; Quinn C; Day L; Larkin M; Palace J; Berrih-Aknin S; Claeys KG; Muppidi S; Mantegazza R; Saccà F; Meisel A; Bassez G; Murai H; Janssen MF
    BMJ Open; 2023 Jan; 13(1):e066445. PubMed ID: 36720569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physician- and patient-reported perspectives on myasthenia gravis in Europe: a real-world survey.
    Mahic M; Bozorg A; DeCourcy J; Golden K; Gibson G; Taylor C; Scowcroft A
    Orphanet J Rare Dis; 2023 Jun; 18(1):169. PubMed ID: 37386469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
    Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
    Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
    Howard JF; Bril V; Vu T; Karam C; Peric S; Margania T; Murai H; Bilinska M; Shakarishvili R; Smilowski M; Guglietta A; Ulrichts P; Vangeneugden T; Utsugisawa K; Verschuuren J; Mantegazza R;
    Lancet Neurol; 2021 Jul; 20(7):526-536. PubMed ID: 34146511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding side effects of therapy for myasthenia gravis and their impact on daily life.
    Bacci ED; Coyne KS; Poon JL; Harris L; Boscoe AN
    BMC Neurol; 2019 Dec; 19(1):335. PubMed ID: 31864345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of framing and communicating COVID-19 vaccine side-effect risks on vaccine intentions for adults in the UK and the USA: A structured summary of a study protocol for a randomized controlled trial.
    Sudharsanan N; Favaretti C; Hachaturyan V; Bärnighausen T; Vandormael A
    Trials; 2021 Sep; 22(1):592. PubMed ID: 34488843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome in patients with myasthenia gravis: one decade longitudinal study.
    Bozovic I; Ilic Zivojinovic J; Peric S; Kostic M; Ivanovic V; Lavrnic D; Basta I
    J Neurol; 2022 Apr; 269(4):2039-2045. PubMed ID: 34480608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma exchange for myasthenia gravis.
    Gajdos P; Chevret S; Toyka K
    Cochrane Database Syst Rev; 2002; 2002(4):CD002275. PubMed ID: 12519572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Prospective Study to Evaluate the Possible Role of Cholecalciferol Supplementation on Autoimmunity in Hashimoto's Thyroiditis.
    Bhakat B; Pal J; Das S; Charaborty SK; SircarMedical NR; Kolkata ; RGKar ; NorthBengal ; Siliguri
    J Assoc Physicians India; 2023 Jan; 71(1):1. PubMed ID: 37116030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical and surgical treatment for ocular myasthenia.
    Benatar M; Kaminski H
    Cochrane Database Syst Rev; 2006 Apr; (2):CD005081. PubMed ID: 16625623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myasthenia gravis: regimens and regimen-associated problems in adults.
    Hood LJ
    J Neurosci Nurs; 1990 Dec; 22(6):358-64. PubMed ID: 2148764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis: The RINOMAX Randomized Clinical Trial.
    Piehl F; Eriksson-Dufva A; Budzianowska A; Feresiadou A; Hansson W; Hietala MA; Håkansson I; Johansson R; Jons D; Kmezic I; Lindberg C; Lindh J; Lundin F; Nygren I; Punga AR; Press R; Samuelsson K; Sundström P; Wickberg O; Brauner S; Frisell T
    JAMA Neurol; 2022 Nov; 79(11):1105-1112. PubMed ID: 36121672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring outcomes and characteristics of myasthenia gravis: Rationale, aims and design of registry - The EXPLORE-MG registry.
    Anil R; Kumar A; Alaparthi S; Sharma A; Nye JL; Roy B; O'Connor KC; Nowak RJ
    J Neurol Sci; 2020 Jul; 414():116830. PubMed ID: 32388060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of quality of life in Brazilian patients with myasthenia gravis.
    Mourão AM; Gomez RS; Barbosa LS; Freitas Dda S; Comini-Frota ER; Kummer A; Lemos SM; Teixeira AL
    Clinics (Sao Paulo); 2016 Jul; 71(7):370-4. PubMed ID: 27464292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acetylcholinesterase inhibitor treatment for myasthenia gravis.
    Mehndiratta MM; Pandey S; Kuntzer T
    Cochrane Database Syst Rev; 2011 Feb; (2):CD006986. PubMed ID: 21328290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics and burden of illness in patients with hereditary angioedema: findings from a multinational patient survey.
    Mendivil J; Murphy R; de la Cruz M; Janssen E; Boysen HB; Jain G; Aygören-Pürsün E; Hirji I; Devercelli G
    Orphanet J Rare Dis; 2021 Feb; 16(1):94. PubMed ID: 33602292
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.